RT Journal Article
SR Electronic
T1 Early Prediction of COVID-19 Severity Using Extracellular Vesicles and Extracellular RNAs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.14.20212340
DO 10.1101/2020.10.14.20212340
A1 Yu Fujita
A1 Tokio Hoshina
A1 Juntaro Matsuzaki
A1 Tsukasa Kadota
A1 Shota Fujimoto
A1 Hironori Kawamoto
A1 Naoaki Watanabe
A1 Kenji Sawaki
A1 Yohei Sakamoto
A1 Makiko Miyajima
A1 Kwangyole Lee
A1 Kazuhiko Nakaharai
A1 Tetsuya Horino
A1 Ryo Nakagawa
A1 Jun Araya
A1 Mitsuru Miyato
A1 Masaki Yoshida
A1 Kazuyoshi Kuwano
A1 Takahiro Ochiya
YR 2020
UL http://medrxiv.org/content/early/2020/10/16/2020.10.14.20212340.abstract
AB The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission. After standard therapy without corticosteroids, 9 of the 31 patients developed severe COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. Among these markers, EV COPB2 has the best predictive value for severe deterioration of COVID-19 patients in this cohort. This type of information concerning functional extracellular component profiles could have great value for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy.Competing Interest StatementMitsuru Miyato is a chief executive officer, and Takahiro Ochiya is a chief scientific advisor of International Space Medical Co., Ltd. The other authors have declared that no conflict of interest exists.Funding StatementThis work was supported by International Space Medical Co., Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study involving collection of COVID-19 serum samples was approved by the Institutional Review Board at The Jikei University School of Medicine (Number: 32-055(10130)). The protocol did not require informed consent, and patients were given the choice of opting out of the study. For collection of healthy control serum samples, this study was approved by the Institutional Review Board at The Institute of Medical Science, The University of Tokyo (Number: 28-19-0907). Written informed consent was provided by all healthy donors before sample acquisition, in accordance with Declaration of Helsinki principles.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGSE data will be opened.